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One Sentence Summary 
Asymptomatic outcome of dengue virus infection is determined by increased activation of the 
adaptive immune compartment and proper feedback mechanisms leading to elimination of 
viral infection without excessive immune activation observed in clinical dengue patients.  
Abstract  
 
Dengue is the most prevalent arthropod-borne viral disease. Clinical symptoms of dengue 
virus (DENV) infection range from classical mild dengue fever to severe, life-threatening 
dengue shock syndrome. However, most DENV infections cause few or no symptoms. 
Asymptomatic DENV-infected patients provide a unique opportunity to decipher the host 
immune responses leading to virus elimination without negative impact on t       v     ’  
health. We used an integrated approach of transcriptional profiling and immunological 
analysis comparing a Cambodian population of strictly asymptomatic viremic individuals 
with clinical dengue patients. Whereas inflammatory pathways and innate immune responses 
were similar between asymptomatic individuals and clinical dengue patients, expression of 
proteins related to antigen presentation and subsequent T and B cell activation pathways were 
differentially regulated, independent of viral load or previous DENV infection. Feedback 
mechanisms controlled the immune response in asymptomatic viremic individuals as 
demonstrated by increased activation of T cell apoptosis-        p   w y      F γ IIB 
signaling associated with decreased anti-DENV specific antibody concentrations. Taken 
together, our data illustrate that symptom-free DENV infection in children is determined by 
increased activation of the adaptive immune compartment and proper control mechanisms 
leading to elimination of viral infection without excessive immune activation, having 
implications for novel vaccine development strategies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Introduction 
Dengue is the most prevalent arthropod-borne viral disease. Every year, dengue virus 
(DENV) is estimated to cause at least 50 million infections, 500,000 hospitalizations, and 
12,500 deaths (1-4). Fifty percent of the world population is considered at risk of infection 
(2). DENV belongs to the genus Flavivirus and is transmitted by Aedes spp. mosquitoes and 
consists of 4 antigenically distinct serotypes (DENV-1 to DENV-4). Each of the four DENV 
serotypes can cause dengue fever (5, 6), occasionally progressing to severe dengue, a life-
threatening condition characterized by a cytokine storm, vascular leakage and shock (7-9). 
Despite more than 30 years of research on dengue pathophysiology, the mechanisms leading 
to severe clinical outcome upon DENV infection remain elusive, and likely involve complex 
interactions between viral, immunological, and human genetic factors (10). Increased risk of 
severe dengue during secondary infection could be due to antibody dependent enhancement 
(ADE) where low affinity, serotype cross-reactive antibodies increase viral infection of 
antigen presenting cells or by cross-reactive cytotoxic T cells (11-13). However, it remains to 
be investigated to what extent these mechanisms contribute to human pathogenesis. 
Importantly, a large part of DENV infections remain subclinical, resulting in insufficient 
     m             p    p     ’      y         (1, 14, 15). While having no direct effect on one 
ind v     ’   ealth, subclinical infections nevertheless have major epidemiological 
consequences such as viral dissemination and maintenance, leading to the immune priming of 
naïve populations, which may impact the clinical outcome of subsequent infections (16, 17). 
Finding subclinical cases during routine surveillance studies is highly challenging and clear 
definitions are lacking. This phenomenon therefore remains poorly documented and 
understood. “ ubclinical infection” mostly refers to DENV infection without major 
symptoms requiring medical attention, while “asymptomatic infection”  s a confirmed DENV 
infection in the complete absence of any reported or detected symptoms (17-20). 
Epidemiological risk factors such as age, time interval between consecutive DENV 
infections, previous DENV infecting serotype and the concentrations of pre-existing 
heterotypic neutralizing antibodies have been associated with subclinical or asymptomatic 
outcome after DENV infection (15, 21-23). The molecular and immunological mechanisms 
underlying control of DENV infection without disease manifestations, however, remain 
unknown.  
In order to identify host mechanisms involved in control of DENV infection without any 
clinical symptoms, we used an integrated approach of transcriptional profiling and 
immunological analysis of Cambodian children which are viremic DENV-infected and 
strictly asymptomatic compared to viremic patients with clinical signs of dengue. Our results 
show distinct transcriptional profiles in asymptomatic individuals, with an increased 
activation of the adaptive immune compartment and proper regulatory mechanisms leading to 
control of viral infection without excessive immune activation.  
 
Results 
Patient characteristics, viral load and cell count 
A total of 85 DENV-infected children were included in the present study. Dengue infection 
was confirmed in all individuals by detection of viral RNA in serum as measured by viral 
RNA copies (Table 1, total cohort). During dengue transmission seasons of 2012 and 2013, 
clinico-epidemiological investigations were conducted around households to identify DENV-
infected individuals without symptoms (17). Nine individuals remained strictly asymptomatic 
at the time of inclusion and during the 10-day follow-up period. Rigorous definition of 
asymptomatic infection was applied, with complete absence of reported or detected clinical 
symptoms (including but not limited to retro-orbital pain, headache, rash, fever, abdominal 
pain), and DENV infection was confirmed by DENV positive real time quantitative PCR 
(qRT-PCR) (17). For all clinical dengue patients, blood collection was performed at 3 ± 2 
days after fever onset. Clinical dengue patients included 37% of dengue fever cases, 38% of 
dengue hemorrhagic fever and 25% of dengue shock syndrome patients (Table 1, total 
cohort), according to WHO 1997 classification criteria (24). 
Several types of analysis were performed: gene expression analysis on purified PBMC, 
antibody and cytokine measurements in serum and immunophenotyping. For all analysis, 
samples were selected based on availability and quality of the samples. Importantly, 
comparing gene expression profiles of clinical dengue patients and asymptomatic dengue-
infected individuals, we only studied patients infected by dengue serotype 1 (DENV-1), the 
main circulating viral serotype in Cambodia at the time of study, and with comparable viral 
loads as measured by viral RNA copies between asymptomatic cases and clinical dengue 
patients in order to minimize confounding factors (Figure 1A and Table 1, analysis 1). Eight 
strictly asymptomatic viremic individuals and 25 dengue patients experiencing symptoms 
were included. Of these, secondary infections were identified in 50% of the asymptomatic 
cases and in 100% of the clinical dengue cases (Table 1). Serum cytokine and antibody 
measurements were performed on eight asymptomatic dengue samples and 58 symptomatic 
individuals, which included all patients analyzed for differential gene expression (Table 1, 
analysis 2). We performed phenotypic analysis on purified PBMC for six out of nine 
asymptomatic dengue cases, including one DENV-4 infected case, and eighteen additional 
clinical dengue cases that were not included in the gene expression or serum cytokine analysis 
but that had readily available DMSO-frozen PBMC of sufficient quality. The demographic 
characteristics of these patients were similar to those of other clinical dengue patients (Table 
1, analysis 3). In order to investigate correlations between gene expression and viral load, we 
analyzed gene expression profiles in 36 clinical dengue patients and 8 asymptomatic 
individuals (Table 1, analysis 4).  
Cell populations composition was similar between asymptomatic and clinical dengue 
subjects, with similar percentages of innate and adaptive immune cells (CD14
+
 monocytes, 
Lin-CD11c
+
 dendritic cells, CD19
+
 B cells, CD335
+
 NK cells) (Figure 1B), with the 
exception of T cells: We observed an increase in percentage of CD4
+
 T cells and a decrease in 
CD8
+
 T cells in the lymphocyte gate in asymptomatic viremic individuals. Correspondingly, 
the CD4/CD8 ratio was inversed in clinical dengue patients (median: 1.2, IQR: 1.0-2.2 versus 
median: 0.8, IQR: 0.4-1.5, respectively, P<0.01) (Figure 1C, D), suggesting deregulated T 
cell responses children with clinical dengue infection (25) 
 
Transcriptional signatures discriminate between asymptomatic and clinical dengue patients. 
In order to gain insights into the mechanisms contributing to asymptomatic outcome of 
dengue infection, differential gene expression analysis was performed on purified PBMC of 8 
asymptomatic and 25 clinical dengue patients. A total of 1663 genes were differentially 
expressed, of which 1045 genes were upregulated and 618 genes were repressed in 
asymptomatic viremic individuals vs. clinical dengue patients (Table S1). A hierarchical 
cluster analysis was carried out on the differentially expressed genes. All asymptomatic 
patients clustered together, indicating that they exhibit similar gene expression patterns as 
depicted by the heatmap (Figure 2A). We performed gene ontology enrichment analysis as 
implemented in GOrilla in order to identify biological processes diverging the most between 
asymptomatic and clinical dengue individuals (26). The most significant differentially 
regulated processes were related to immune processes, with 12 out of the 20 most significant 
processes related to immune response and immune activation (Figure 2B, Table S2).  
We further explored pathways significantly enriched in the list of differentially expressed 
genes between asymptomatic viremic individuals and clinical dengue patients using Ingenuity 
Pathway Analysis (IPA) (27). Three hundred and seventy-nine canonical pathways were 
found to be significantly different as a result of pathway enrichment analysis for the 
differentially expressed genes between asymptomatic viremic and clinical dengue patients 
(Figure 2C and Table S3). Of major importance, immune processes were activated mainly in 
asymptomatic viremic individuals.  
Bias may occur due to the difference of immune status between groups as 50% of 
asymptomatic DENV infection were primary infections whereas all 25 clinical dengue 
patients were undergoing a secondary infection. To explore this, we performed an analysis 
excluding the four primary asymptomatic DENV-infected individuals. Despite lower numbers 
of differentially expressed genes and associated pathways, similar results were obtained, 
although the significance threshold was not reached in all comparisons (Table S1-S3).  
In order to verify that genes differentially expressed in asymptomatic viremic individuals 
were up or down-regulated compared to healthy controls, we compared our results with 
previously published genes differential expressed between 8 healthy children and 41 clinical 
dengue cases from Nicaragua (28). Of 1385 genes differentially expressed between 
asymptomatic viremic children and clinical dengue patients, only 38 genes were overlapping 
amongst the 204 differentially expressed genes found between healthy controls and clinical 
dengue patients (Figure 2D and Table S1)  
Taken together, transcriptional profiling can differentiate between DENV-1 infected 
individuals with or without clinical symptoms, irrespective of viral load and immune status. 
Most gene expression changes are related to immune responses, which are enriched in 
asymptomatic individuals.  
 
No major differences in innate immune responses between asymptomatic and clinical dengue 
patients 
Investigating more in detail immune processes differentially regulated between DENV- 
infected individuals with or without clinical symptoms revealed no major differences in 
activation of innate immune responses. IPA pathways such as regulation of innate immunity, 
antiviral innate immunity, activation of pattern recognition receptors, IL-8 signaling and type 
I or II IFN-regulated pathways did not differentiate between clinical dengue and 
asymptomatic infection (data not shown). Consistently with the transcriptomic results, 
signature cytokines produced by innate immune cells such as IL-8, IL-15 CCL3 and CCL4 
displayed comparable serum concentrations between groups (Figure 3A), and serum 
concentrations of key-cytokines regulating innate immune functions and activation were 
similar between both groups (Figure S1). IFN, a cytokine critical for both innate and 
adaptive immunity against viral infections, was increased in asymptomatic viremic 
individuals (Figure S1). In addition, serum concentrations of inflammatory cytokines such as 
TNFα and IL-6 were not different between asymptomatic viremic and clinical dengue 
patients. Even though serum concentrations of IL-1β were below the detection limit, a similar 
regulation of IL-1 regulated gene expression, irrespective of clinical outcome, was observed. 
Furthermore, in asymptomatic viremic individuals we observed a downregulation of IL-1 
receptor-associated kinase 2 (IRAK2), a serine/threonine kinase associated with IL-1 receptor 
upon stimulation (Table S1).  
Comparing the cytokine profiles of the four asymptomatic cases undergoing secondary 
infection with the clinical dengue patients undergoing secondary infection yielded similar 
results (Figure S2 and S3).  
Taken together, these data suggest that activation of innate immune pathways are similarly 
regulated in asymptomatic and symptomatic viremic dengue-infected children.  
 Asymptomatic viremic individuals show differentially regulated pathways related to antigen 
presentation  
The most significant activated pathway in asymptomatic individuals was “nuclear factor of 
activated T cells (NFAT) mediated regulation of immune response” (Figure 2C, Table S3). 
NFATs are major regulators of the adaptive immune response and are expressed after 
antigenic stimulation of lymphocytes (29). Hence, we first investigated the regulation of 
antigen presentation in asymptomatic viremic individuals. Indeed, pathway analysis revealed 
a differential regulation of the antigen presentation pathway and upregulation of dendritic cell 
maturation in asymptomatic viremic individuals (Figure 2C, Table S3). Genes upregulated 2 
        m    (L g2F  ≥ 1) in asymptomatic viremic individuals included CIITA, CD74, and 
various HLA genes. In stark contrast however, the CD86 co-stimulatory molecule was 
significantly downregulated (Table S1). 
These data were confirmed by ex vivo phenotypic analysis of PBMC collected from both 
groups. HLA-DR expression was increased on CD14
+
 monocytes of asymptomatic viremic 
individuals) and could be induced by the observed increase in serum IFN concentrations. 
(Figure 4B and Figure S1). In contrast, CD86 expression was decreased on both CD14
+
 
monocytes and Lin
-
CD11c
+
 dendritic cells (Figure 4B). Serum concentrations of IL-12 and 
IL-23, both secreted by antigen-presenting cells and indicative of their activation, were 
increased in asymptomatic viremic individuals compared to clinical dengue patients (Figure 
4C). Avoiding bias due to immune status, we compared secondary cases of dengue infection 
only. Despite the low number of samples, significant differences were observed between 
asymptomatic viremic individuals and symptomatic patients for most parameters (Figure S4).  
Taken together these transcriptional and protein expression data suggest that activation of 
APC is differentially regulated in asymptomatic viremic children, possibly including 
feedback-regulation trough decreased CD86 expression on APC  (30, 31).  
 
Increased T cell activation and T cell apoptosis in asymptomatic viremic individuals 
In accordance with the observed upregulation of the antigen-presentation pathway  PK θ 
signaling in T lymphocytes was highly activated in asymptomatic viremic individuals. PK θ 
is an essential component of the T cell supramolecular activation cluster and mediates several 
crucial functions in TCR signaling. Genes upregulated 2         m    (L g2F  ≥ 1)    
asymptomatic viremic individuals included AKT3, SOS1, PAK1 and SLAMF6 (Table S1 and 
Figure 5A). In accordance, several T cell co-stimulatory pathways were upregulated in 
asymptomatic viremic individuals such as ICOS-ICOSL signaling in T helper cells and CD28 
and CTLA-4 signaling in cytotoxic T lymphocytes (Figure 2C, Table S3). In addition, IL-2 
cytokine serum concentration was increased and IL-2 signaling pathway was upregulated in 
asymptomatic viremic individuals (Figure 5B). CD69, an early activation marker expressed 
on many cell types, was found to be significantly upregulated 2 fold or more (Table S1). 
Indeed, CD69 expression was significantly higher on both CD4
+
 and CD8
+
 T cell populations 
in asymptomatic viremic individuals (Figure 5C). Comparing only secondary cases of DENV 
infected children yielded similar upregulated genes and pathways in asymptomatic 
individuals (Table S1 and S3). In addition, IL-2 serum concentrations and CD69 expression 
remained elevated even though the sample size was small (Figure S5).  
One of the most significantly activated pathways in asymptomatic viremic individuals is 
implicated in TCR-mediated apoptosis: calcium-induced T Lymphocyte Apoptosis (Figure 
2C), which might correspond to regulative measures against the proliferative response that 
follows TCR stimulation (32). Asymptomatic outcome of DENV infection appears to be 
associated with increased T cell activation and apoptosis.  
 
Upregulation of gene expression pathways leading to plasma cell development and the 
secretion of anti-DENV antibodies correlate with the development of clinical dengue 
We further investigated the association between clinical outcome and B cell responses after 
DENV infection. IPA analysis indicated an activation of the B cell receptor (BCR) signaling 
pathway in asymptomatic viremic individuals with genes such as BANK1 and MS4A1 
(CD20) significantly upregulated 2         m    (L g2F  ≥ 1) (Figure 6A, B). However, 
PI3K signaling in B cells, a pathway activated within seconds after BCR stimulation, was 
inhibited in asymptomatic individuals (Figure 6A). This can be explained by the 2 fold or 
more upregulation of molecules involved in inhibition of B cell activation and differentiation 
         D22  F  L1     F  L6 (L g2F  ≥ 1) (F g    6B) (33). In addition, F γ IIB 
signaling, mediating inhibition of BCR signaling after antigenic stimulation, was activated in 
asymptomatic viremic individuals (Figure 6A).  
Moreover, key transcription factors for plasma cell differentiation, such as PRDM1 (BLIMP-
1) and IRF4 were downregulated at least 2 fold in asymptomatic infections compared to 
clinical dengue patients (L g2F  ≤ -1) (Figure 6B). These gene expression data suggest that 
while B cells are activated in asymptomatic individuals, inhibitory mechanisms preventing 
the differentiation to plasma cells are in place. Conversely, differentiation to plasma cells 
seems to be increased in clinical dengue patients. In accordance with this observation, we 
detected high IL-10 serum concentrations (1.7 (0.0-5.3) versus 24.2 (9.5-38.9) pg/ml, 
P<0.0001) and overexpression of IL-10 transcripts in clinical dengue patients (Figure 6B, C). 
This is specific to IL-10, as IL-21 and IL-4 serum concentrations did not differ between 
patients and clinical dengue patients (Figure 6C and data not shown).  
Finally, to explore the hypothesis that B cell responses and plasmablast development are 
inhibited in asymptomatic dengue infected individuals, as suggested by the gene expression 
data, we investigated the anti-DENV antibody response 8 ± 2 days after inclusion in the 
study. Stratifying samples according to primary or secondary infection, we observed 
decreased concentrations of IgM as measured by MAC-ELISA and a lower hemagglutination 
inhibition (HI) titer in asymptomatic individuals (Figure 6D). Hence, gene expression 
pointing towards a decreased inhibition of B cell activation and increased plasma cell 
differentiation combined with increased serum concentrations of anti-DENV antibodies are 
associated with clinical dengue.  
 
Correlation between viral load and differentially regulated key genes 
Using linear regression models to assess viral load variation in 8 asymptomatic and 36 
clinical dengue patients, we could show a significant association between viral load and 
disease status (Table 1, analysis 4 and Figure S6). In order to investigate effect of genes 
controlling for viral load on the asymptomatic versus clinical outcome, we performed another 
linear regression analysis between gene expression and viral load while taking into account 
disease status using LIMMA (34).  We identified 31 genes that showed correlation with viral 
load as measured by viral RNA copies. None of these genes were significantly differential 
expressed between asymptomatic viremic individuals and clinical dengue patients (Figure 2D 
and Table S1). Interestingly, these genes are involved in negative regulation of viral life 
cycle, viral processing, and viral genome replication (Table S2, 3).   
 
Discussion 
We report herein the identification of differential adaptive immune responses associated with 
the clinical outcome of DENV infection. Indeed, asymptomatic viremic individuals showed 
differential antigen presentation, increased T cell activation and apoptosis, decreased B cell 
activation and plasmablast differentiation. Our study is the first to interrogate the host 
response during viremic, strictly asymptomatic DENV infection.  
Although we controlled for confounding factors such as DENV serotype, viral load as 
measured by viral RNA copies, age and sex in our transcriptomic analysis, 50% of the 8 
asymptomatic viremic individuals were undergoing a primary dengue infection, whereas all 
25 clinical dengue patients were experiencing a secondary dengue infection. Analyzing only 
secondary asymptomatic viremic individuals yielded similar, but less significant differences 
due to the low number of individuals. As our results suggest higher activation of adaptive 
immunity in asymptomatic viremic individuals, this result is unlikely to be biased by primary 
infection in the asymptomatic viremic group. In addition, it is impossible to assess the exact 
timing of infection in ASD which could influence gene expression and T cell activation, 
however, both ASD and CD patients had detectable viral load corresponding to the acute 
phase of disease.     
 Asymptomatic viremic dengue patients clustered together in terms of transcriptome, serum 
cytokine concentrations and cellular phenotype. Interestingly, this appears mainly due to 
immune processes regulation, rather than to stress-mediated pathways associated with viral 
infection. In addition, differences do not appear linked to innate response pathways or 
inflammatory responses. Genes and proteins involved in antigen processing and presentation 
and serum concentrations of both IL-12 and IL-23 were increased in asymptomatic viremic 
individuals suggesting activation of APCs and increased antigen presentation. However, 
expression of CD86 (but not CD80) was tightly regulated on both circulating monocytes and 
dendritic cells, a first evidence that more controlled immune responses are taking place in 
asymptomatic cases (30, 31) 
Our results also revealed increased T cell activation and apoptosis in asymptomatic viremic 
individuals, supporting a role for T cells in the protection from clinical dengue. which has 
major implications for future vaccine development. A decreased CD4/CD8 ratio has 
previously been observed in clinical dengue and could be the result of specific expansion or 
apoptosis of responder subsets, or, alternatively, might be merely due to the young age of our 
study cohort (25, 32, 35).  
Implications of T cells in the control of disease has been suggested in several human and 
mouse studies. The protective function of CD8
+
 T cells was demonstrated by the 
susceptibility of CD8
+
 depleted IFNAR mice to DENV infection, and the observation that 
both serotype-specific and cross-reactive T cells confer protection after peptide vaccination to 
DENV infection (36, 37). In humans, a HLA-linked protective role of CD8
+
 and CD4
+
 T cell 
responses has been observed in a Sri Lankan population (38, 39). Furthermore, CD4
+
 
cytotoxic T cells confer protection against dengue infection ex vivo (35). Finally, increased 
frequencies of DENV-specific CD4
+
 and CD8
+
 T cells were detected in Thai school children 
who subsequently experienced subclinical infection, compared with symptomatic secondary 
DENV infections (40).  
Recently, CD4 and CD8 T cell epitopes of DENV have been mapped in different human 
populations (38, 41-44). CD8
+
 T cell epitopes preferentially cluster in nonstructural proteins 
such as NS3, NS4b and NS5, whereas CD4
+
 T cell epitopes are skewed towards envelope, 
capsid and NS1 epitopes, which are also targeted by the B cell response. Of major 
importance, most of these epitopes are lacking in the licensed dengue vaccine (Dengvaxia®), 
which might affect the generation of an adequate memory T cell response. Hence, our results, 
together with previous findings, could provide an explanation for the observed relatively low 
efficacy of protection against virologically confirmed dengue of all 4 serotypes obtained with 
Dengvaxia® (45-47). These data emphasize the need to re-consider the inclusion of T-cell 
specific epitopes in future vaccine design.  
Our in-depth analysis of the immune response reveals that clinical outcome of dengue 
infection seems to be determined by aberrant control of B cell responses and increased 
plasmablast differentiation. This finding is consistent with previous studies where massive 
expansion of antibody-producing plasmablasts were observed in the blood of severe dengue 
patients (48-51). This expansion observed in clinical dengue cases is probably driven by IL-
10, as we found increased IL-10 transcripts in PBMC and elevated IL-10 serum 
concentrations in these patients. In addition, IL-10 is required for plasmablast differentiation 
of B cells stimulated by DENV-infected monocytes (51). Of note, IL-10 has been associated 
with severe dengue disease and proposed as a marker predicting severity in a Venezuelan 
cohort (52). 
Efforts on understanding the antigenic specificity of the expanded plasmablasts have been 
undertaken, mainly through in vitro production of monoclonal antibodies derived from sorted 
plasmablasts during acute DENV-infection (53-55). However, the proportion of DENV-
specific, circulating plasmablasts and their origin remains unknown, as well as the 
contribution of polyclonal bystander activation to disease pathogenesis. In accordance with 
our observations, a previous study on early/late convalescence samples showed lower serum 
concentrations of anti-DENV antibodies (against PrM and E) in asymptomatic DENV 
infected individuals compared to clinical dengue patients (56). These observations favor the 
hypothesis that antibodies may play a pathogenic role in the risk of development of clinical 
dengue, possibly trough antibody-dependent enhancement, where low affinity, serotype cross-
reactive (i.e. heterologous) antibodies would increase viral infection of APC (monocytes and 
dendritic cells) (11, 12).  
This study is the first to perform an integrated immunologic analysis of strictly asymptomatic 
dengue-infected individuals with confirmed DENV viral load. We investigated PBMC during 
the acute phase of the disease and circulating cells were in an activated state. However, we 
cannot delineate which of the observed phenomena can be attributed to antigen specific 
responses. Therefore, future studies using tools to identify DENV-specific T cells and B cells 
in strictly asymptomatic individuals will be of great value (38, 53) 
One previous report analyzing differential gene expression in asymptomatic DENV-infected 
individuals investigated patients in the convalescent phase of the disease, as demonstrated by 
the absence of detectable viral loads (57). Unsurprisingly, they found that most genes related 
to host defense mechanisms were downregulated.  
We show that control of infection without the concurrent development of clinical symptoms 
is associated with strong and regulated adaptive immune response. Molecules involved in 
antigen presentation are differentially regulated and T cell activation is increased in acute 
DENV-infected asymptomatic individuals, whereas upregulation of gene expression 
pathways leading to plasmablast development and the secretion of anti-DENV antibodies 
correlate with the development of clinical dengue. These results contribute to our 
understanding of the development of symptomatic dengue and will lead to novel strategies for 
future vaccine development.  
 
Materials and Methods 
Patient recruitment and classification 
Study design with identification of dengue index cases and cluster participants was described 
in detail previously (17). In brief, dengue index cases (DIC) were identified from patients 
presenting with acute dengue-like illness between June and October of 2012 and 2013 at 
Kampong Cham City Provincial hospital, at two district hospitals in Kampong Cham 
province, and from villages-based active fever surveillance. A cluster investigation was 
initiated, enrolling all family members in the household and people living within a 200m 
radius of the DIC’  home. DIC and cluster participants were examined during sequential 
visits as described (17). Blood samples were taken from hospitalized patients at two time 
points: one at hospital admission and one at hospital discharge, during the convalescent 
phase. Disease severity of clinical patients was assessed according to the 1997 WHO criteria 
(24). DENV-positive cluster investigation participants were assessed prospectively at D0, D1, 
D2, D3, D4, D5, D6, D7, and D10 for occurrence of clinical symptoms and blood sampling. 
Only patients displaying no clinical symptoms during this follow-up period were considered 
asymptomatic and included in the present study. Serum was stored at -80°C for future 
analysis and PBMC were separated using Ficoll-Paque density gradient centrifugation and 
stored in RNA-later or DMSO until transcriptomic and cellular phenotypic analysis, 
respectively. The study was approved by the National Ethics Committee of Health Research 
of Cambodia and written informed consent of all participants or legal representatives for 
participants under 16 years of age was obtained before inclusion in the study. 
 
Laboratory diagnosis 
DENV infection was confirmed on serum samples collected at admission of hospitalized 
patients or inclusion in the cluster investigation by nested qRT-PCR at the Institut Pasteur in 
Cambodia, the National Reference Center for arboviral diseases in Cambodia (58). 
Serological tests were performed on specimen collected during the acute and convalescent 
phase of the infection in both symptomatic and asymptomatic groups for detection of 
antibodies against DENV. Because of potential cross-reactivity among flaviviruses, all 
specimens were tested for both anti-DENV and anti-Japanese encephalitis virus antibodies 
using an in-house IgM capture ELISA (MAC-ELISA) and (HI) assay as previously described 
(17). Primary or secondary immune status of DENV infections was determined by HI test 
according to WHO criteria (2).  
 
RNA preparation, microarray hybridization and Analysis  
RNA was extracted with an RNeasy kit (Qiagen) and hybridized overnight with the probes 
contained in the Affymetrix Human Transcriptome Array 2.0 (HTA2). Microarray data was 
obtained with an Affymetrix GeneChip scanner 3000. After quality control and data 
normalization, we performed differential gene expression analysis in R using the Limma 
(LInear Models for MicroArray data) package (34). LogFC value (calculated with the 
empirical Bayes method) indicates the log2-fold change for that gene between the subgroups 
of interest. An adjusted p-value cutoff of 0.05 (calculated with Benjamin and Hochberg (BH) 
procedure) and an absolute value greater than 0.6 (corresponding to change in expression 
higher than 1.5) for log2 Fold Change (FC) was considered statistically significant and 
biologically relevant.   
Analyzing all patients included for gene expression analysis showed a significant difference 
in mean viral load between the two groups (Figure S6). Therefore, in order to differentiate the 
effect of genes controlling viral copies and effect of genes affecting asymptomatic vs clinical 
dengue outcome, two ways of analyses were performed: (i) filter out clinical dengue patients 
with high viral titers above 10
6
. The restriction resulted in a dataset of 33 patients (8 
asymptomatic individuals and 25 clinical dengue patients, Table 1, analysis 1) and (ii) 
correlate gene expression levels to viral load and identify key genes associated with viral load 
variation in the two groups (Table 1, analysis 4). Linear regression analysis was implemented 
using the LIMMA package in order to assess the gene expression response to viral load 
variation in asymptomatic individuals and clinical dengue patients. Disease status was 
controlled for by using a component of interaction term between disease status and viral load. 
In order to compare our results to gene expression in healthy controls, we included a 
previously published transcriptomic dataset from Nicaragua (28), involving both clinical 
dengue patients and healthy controls. Using the datasets from these individuals, a list of 
statistically significant differentially expressed genes was constructed (performed at the gene 
rather than transcript level due to different microarray platforms used) and compared to 
analysis 1 (Table S1 and Figure 2D) 
 
Differential Gene Expression Enrichment 
1) Gene ontology enrichment analysis using GOrilla  
We used GOrilla, a tool for gene ontology (GO) vocabulary enrichment analysis, in order to 
identify sets of biological processes that are significantly overrepresented in the list of 
significant differentially expressed genes between asymptomatic and symptomatic dengue 
patients (26). As part of GOrilla analysis, the tool discovers GO terms in a target set of genes 
(differentially expressed genes) versus a background set of genes (gene expression data 
scanned with Affymetrix GeneChip). The discovery of the enriched biological processes is 
accomplished using a hypergeometric model which computes an enrichment p-value for each 
overrepresented process (59). We selected 10
-3
 as an enrichment p-value threshold to identify 
significantly overrepresented processes. In addition to p-value, Gorilla outputs FDR q-value 
as an adjusted p-value for multiple testing using Benjamin and Hochberg (BH) procedure, and 
the list of genes associated with the process that appear in the top twenty of the list. 
2) Pathway enrichment analysis using Ingenuity Pathway Analysis software 
We used QIAGEN Ingenuity® Pathway Analysis (IPA® QIAGEN Redwood City, 
www.qiagen.com/ingenuity) in order to identify the immunity-related canonical pathways 
significantly enriched in the list of differentially expressed genes between asymptomatic 
viremic and clinical dengue patients. IPA calculates significance values for canonical 
pathways using Fisher's exact test right-tailed (27). The significance indicates the probability 
of association of the given genes with the canonical pathway by chance. IPA considers a 
canonical pathway to be significant and non-randomly associated with the given genes if the 
p-value is below a threshold value of 0.05. In addition to the p-value, IPA outputs other 
statistical measures for each canonical pathway; z-score value gives the pathway standard 
deviation and can be used to predict the pathway activation state, and ratio value indicates the 
strength of association between the pathway and the list of differentially expressed genes.  
 
Serum cytokine measurements 
Cytokines serum concentrations were measured with the Bio-Plex Pro Human cytokine 27-
plex and Bio-Plex Pro Human Th17 cytokine panel 15-plex assay (Biorad) and analyzed on a 
Luminex Magpix system (Millipore). 
 
PBMC phenotyping 
PBMC were thawed, washed and counted in PBS/BSA and stained for following surface 
markers: CD11c PE, CD3 PercPcy5.5, CD335 PercPcy5.5, HLA-DR FITC, CD86 BV421, 
CD8 PE-cy7, CD4 PercPcy5.5, CD69 BV421, CD19 APC-cy7 and analyzed on a 
FACSCantoII (BD). Data analysis was performed with FlowJo software.  
 
Statistics 
Statistical analysis was performed using GraphPad Prism (version 5.0; GraphPad, San Diego, 
CA) for the analysis of IgM and HI data, serum cytokine data and PBMC phenotyping data. 
Differences between groups of research subjects were analyzed for statistical significance 
with Mann-Whitney test. A p-v     ≤ 0.05 was considered significant. 
 
Supplementary Materials 
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Table S3 
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Figures 
 
Fig. 1. Characteristics of asymptomatic individuals and clinical dengue patients. (A) Viral 
load as measured by qRT-PCR (as viral RNA copies/ml plasma) and days of fever for all 
patients included in transcriptome analysis. (B-D) Percentages of cells subsets and ratio as 
determined by cell surface marker expression. ASD: asymptomatic dengue (n = 6), CD: 
clinical dengue (n = 18). Bar represent median with interquartile range. P-values were 
obtained with Mann-Whitney test.  
 
Fig. 2. Transcriptional signatures discriminate between asymptomatic and clinical dengue 
patients. (A) Unsupervised hierarchically clustered heatmap of the genes differentially 
expressed between asymptomatic dengue (ASD, n = 8) and clinical dengue patients (CD, n = 
25). (B) Top immunity-related molecular processes found as a result of gene ontology 
enrichment analysis using the GOrilla tool. The significance of the observed enrichment for 
GO molecular processes was estimated by the p-value plotted on base 10 logarithmic scale. 
The enrichment score reflects the strength of association between input gene expression and 
enriched molecular processes. (C) Immunity-related canonical pathways found as a result of 
pathway enrichment analysis using the IPA software. The significance of the association 
between gene expressions and canonical pathway was estimated by the p-value plotted on 
base 10 logarithmic scale and the ratio value reflects its strength. The z-score reflects the 
activation state of the canonical pathway (activated in asymptomatic dengue: z-score>0; 
inhibited in asymptomatic dengue: z-score<0). (D) Venn diagram showed number of 
overlapping genes between asymptomatic individuals versus clinical dengue patients; healthy 
controls versus clinical dengue patients and viral load response. 
 
Fig. 3. Serum cytokines related to innate immune responses and inflammation are not 
associated with clinical outcome of dengue infection. (A, B) Serum concentrations of various 
cytokines (pg/ml) measured by Luminex in asymptomatic dengue-infected individuals (ASD, 
n = 8) and clinical dengue patients (CD, n = 58). Line represents median. P-values were 
obtained with Mann-Whitney test.  
 
Fig. 4. Asymptomatic viremic individuals show differentially regulated pathways and 
molecules related to antigen presentation. (A) Antigen presentation pathway showing 
differentially expressed genes, adapted from IPA. Red: upregulated in ASD, green: 
downregulated in ASD. (B) Representative histograms of HLA-DR and CD86 expression on 
CD14
+
 monocytes and Lin
-
CD11c
+
 dendritic cells of asymptomatic dengue-infected 
individuals (ASD, grey) and clinical dengue patients (CD, white). Data is summarized on the 
right, where lines represent median and interquartile range. ASD: n = 6, CD: n = 18. (C) 
Serum concentrations of IL-12 and IL-23 (pg/ml) measured by Luminex in asymptomatic 
dengue-infected individuals (ASD, n = 8) and clinical dengue patients (CD, n = 58). Line 
represents median. P-values were obtained with Mann-Whitney test.  
 
Fig. 5. Increased T cell activation in asymptomatic viremic individuals. (A) PK θ   g     g 
in T lymphocytes, adapted from IPA. Red: upregulated in ASD, green: downregulated in 
ASD. (B) Serum concentrations of IL-2 (pg/ml) measured by Luminex in asymptomatic 
dengue-infected individuals (ASD, n = 8) and clinical dengue patients (CD, n = 58). Line 
represents median. (C) Representative dot plots of CD69 expression on both CD4
+
 and CD8
+
 
T cells. ASD: asymptomatic dengue (n = 6), CD: clinical dengue (n = 18). Data is 
summarized on the right, where lines represent median and interquartile range. P-values were 
obtained with Mann-Whitney test.  
 
Fig. 6. Increased plasmablast differentiation in clinical dengue patients. (A) Ingenuity 
canonical pathways associated with B cell biology. Ratio indicates the strength of association 
between the pathway and the list of differentially expressed genes. The z-score reflects the 
activation state of the canonical pathway (activated in asymptomatic dengue: z-score>0; 
inhibited in asymptomatic dengue: z-score<0). (B) Summary of genes associated with B cell 
biology. Adjusted p-value was calculated using Benjamin and Hochberg (BH) procedure. 
LogFC indicates the log2-fold change for the gene between asymptomatic dengue and clinical 
dengue infection. (C) Serum concentrations of IL-10 and IL-21 (pg/ml) measured by 
Luminex in asymptomatic dengue-infected individuals (ASD, n = 8) and clinical dengue 
patients (CD, n = 58). Line represents median. (D) Left: Serum anti-DENV IgM as measured 
by MAC-ELISA, where optical density (OD) is reported. Right: Haemagglutination inhibition 
test where the maximum dilution preventing agglutination is shown. Patients are stratified 
according to immune status. Asymptomatic dengue-infected individuals (ASD, n = 8) and 
clinical dengue patients (CD, n = 58). Sera were analyzed 8 ± 2 days after inclusion in the 
study. Line represents median. P-values were obtained with Mann-Whitney test. 
 
Tables 
 
Table 1. Demographic data and clinical parameters of the studied populations. Patients are 
characterized according to WHO1997 criteria. DENV serotype and viral load was determined 
by qRT-PCR. Primary or secondary infection was determined by HI test on acute and 
convalescent samples. N/A: not applicable. CD: clinical dengue, ASD: asymptomatic dengue-
infected individuals.  
 Supplementary Materials 
 
 
Table S1. Overall comparison of significant gene expressions: (i) differentially expressed 
between asymptomatic viremic individuals (primary and secondary infection) and clinical 
dengue patients, (ii) differentially expressed between asymptomatic viremic individuals 
(secondary infection) and clinical dengue patients, (iii) differentially expressed between 
healthy controls and clinical dengue patients, (iv) responded to viral load variation in 
asymptomatic viremic individuals and clinical dengue patients.  All the gene expressions 
were obtained by Limma. Adjusted p-value was calculated using Benjamin and Hochberg 
(BH) procedure. LogFC in differential expression analysis indicates the log2-fold change for 
the gene between the compared groups (positive: upregulated in first group, negative: 
downregulated in first group) 
 
Table S2. Overall comparison of significant molecular processes obtained by gene ontology 
enrichment analysis on the significant genes. The enrichment analysis was performed using 
GOrilla.  FDR q-value is an adjusted p-value for multiple testing calculated using Benjamin 
and Hochberg (BH) procedure.  
 
Table S3. Overall comparison of canonical pathways obtained by pathway enrichment 
analysis on the significant genes.  The enrichment analysis was performed using ingenuity 
pathway analysis. Ratio indicates the strength of association between the pathway and the list 
of expressed genes. The z-score in differential expression analysis reflects the activation state 
of the canonical pathway between the compared groups (z > 0: activated in first group; z < 0: 
inhibited in first group).  
 
 
Fig. S1. Serum cytokines related to innate immune responses and inflammation are not 
associated with clinical outcome of dengue infection. (A, B) Serum concentrations of various 
cytokines (pg/ml) measured by Luminex in asymptomatic dengue-infected individuals (ASD, 
n = 8) and clinical dengue patients (CD, n = 58). Line represents median. P-values were 
obtained with Mann-Whitney test.  
 
Fig. S2 and Fig. S3. Serum cytokines related to innate immune responses and inflammation 
are not associated with clinical outcome of dengue infection in individuals undergoing 
secondary DENV-infection. Serum concentrations of various cytokines (pg/ml) measured by 
Luminex in asymptomatic dengue-infected individuals (ASD, n = 4) and clinical dengue 
patients (CD, n = 50). Line represents median. P-values were obtained with Mann-Whitney 
test.  
 
Fig. S4. Asymptomatic viremic individuals undergoing secondary DENV-infection show 
differentially regulated pathways and molecules related to antigen presentation. (A) 
Expression of HLA-DR and CD86 on monocytes and dendritic cells. Lines represent median 
and interquartile range. ASD: n = 3, CD: n = 17. (B) Serum concentrations of IL-12 and IL-
23 (pg/ml) measured by Luminex in asymptomatic dengue-infected individuals (ASD, n = 4) 
and clinical dengue patients (CD, n = 50). Line represents median. P-values were obtained 
with Mann-Whitney test. 
 
Fig. S5. Increased T cell activation in asymptomatic viremic individuals undergoing 
secondary DENV-infection. (A) CD69 expression both CD4
+
 and CD8
+
 T cells. ASD: 
asymptomatic dengue (n = 3), CD: clinical dengue (n = 17). Lines represent median and 
interquartile range. (B) Serum concentrations of IL-2 (pg/ml) measured by Luminex in 
asymptomatic dengue-infected individuals (ASD, n = 4) and clinical dengue patients (CD, n = 
50). Line represents median. P-values were obtained with Mann-Whitney test. 
 
Fig. S6. Viral load in asymptomatic and clinical dengue patients. (A) Visual comparison 
between the two groups showed a clear overlap in viral load levels in analysis 1 (n = 33), but 
in analysis 4 (n = 44) the clinical dengue patient group appeared to have higher viral load 
levels. (B) Comparison between two linear regression models correlating log10 (viral load) to 
the disease state in the two groups. In analysis 1 (n = 33), the model showed an average viral 
load of 10^3.83 in the asymptomatic reference group and a mean difference of 10^0.72 
between the two groups. The model showed no significant association between viral load and 
disease state. In analysis 4 (n = 44), the model showed a higher mean difference of 10^1.68 
and a significant association between viral load and disease state. 
 
 
 
 
